Dr. Reddy's Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of TocilizumabBusiness Wire • 06/05/23
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.Business Wire • 05/05/23
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.Business Wire • 04/21/23
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative DiseasesBusiness Wire • 03/20/23
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma's U.S. Generic Prescription Product PortfolioBusiness Wire • 02/27/23
Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd yearBusiness Wire • 02/08/23
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. MarketBusiness Wire • 01/27/23
Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., EuropeBusiness Wire • 01/20/23
Dr. Reddy's Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of TocilizumabBusiness Wire • 12/19/22